Schizophrenia Clinical Trials
There are 305 actively recruiting schizophrenia clinical trials across 44 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 1, Phase 4, Early Phase 1. Top locations include Atlanta, Georgia, United States, Chicago, Illinois, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.
Schizophrenia Trials at a Glance
305 actively recruiting trials for schizophrenia are listed on ClinicalTrialsFinder across 6 cities in 44 countries. The largest study group is Not Applicable with 165 trials, with the heaviest enrollment activity in Atlanta, Chicago, and Houston. Lead sponsors running schizophrenia studies include Shanghai Mental Health Center, China Medical University Hospital, and Centre for Addiction and Mental Health.
Browse schizophrenia trials by phase
Top cities for schizophrenia trials
Treatments under study
Understanding Schizophrenia Clinical Trials
Every antipsychotic medication used to treat schizophrenia today, from first-generation drugs like chlorpromazine to newer options like cariprazine (Vraylar) and lumateperone (Caplyta), was developed through clinical trials. In 2024, the FDA approved cobenfy (xanomeline-trospium), the first truly novel mechanism for schizophrenia treatment in decades, targeting muscarinic receptors rather than dopamine, a breakthrough that only became possible through years of clinical trial research. For the approximately 2.8 million adults in the United States living with schizophrenia, ongoing trials are exploring treatments that aim to address not just psychotic symptoms but also the cognitive and social difficulties that current medications often leave untreated.
Why Consider a Clinical Trial?
Frequently Asked Questions
Common questions about Schizophrenia clinical trials
Yes, many trials allow participants to continue their current medication. Some studies test add-on treatments that supplement your existing antipsychotic, while others may require a supervised medication change. The research team will explain exactly what is required and will not make any changes without your consent.
Yes, cognitive impairment is a major focus of current schizophrenia research. Trials are testing pro-cognitive medications, computerized cognitive training programs, and combination approaches. These studies typically measure improvements in memory, attention, and problem-solving using standardized neuropsychological tests.
All schizophrenia trials have safety protocols for symptom worsening. If your symptoms significantly worsen, the research team can provide rescue medication, adjust your treatment, or withdraw you from the study with a safe transition plan back to standard care. Your wellbeing always takes priority over the research protocol.
Most schizophrenia trials welcome caregiver involvement. Family members can attend study visits, help with transportation, and assist with medication adherence. Some studies specifically include caregiver assessments as part of the outcome measures. The research team will work with you and your support network.
Most schizophrenia trials are conducted on an outpatient basis, meaning you attend scheduled visits at the research site but live at home. Some acute-phase trials may begin with a brief inpatient stabilization period. The study design will be clearly explained before you consent to participate.
Showing 1–20 of 305 trials